Glucocorticoid use in rheumatoid arthritis: Benefits, mechanisms, and risks

Clinical and Experimental Rheumatology

Volumn 22, Issue 5 SUPPL. 35, 2004, Pages

  Townsend, Henry B ^a   Saag, Kenneth G ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Disease modifying anti rheumatic drugs (DMARDs); Glucocorticoid induced osteoporosis (GIOP); Lucocorticoids; Non steroidal anti inflammatory drugs (NSAIDS); Rheumatoid arthritis

Indexed keywords

ANTIBIOTIC AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIRHEUMATIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; GLUCOCORTICOID; HORMONE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PARATHYROID HORMONE[1-34]; PLACEBO; PREDNISOLONE; PREDNISONE; PROTON PUMP INHIBITOR; SALAZOSULFAPYRIDINE; STEROID; VITAMIN D; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID RECEPTOR;

ADRENAL INSUFFICIENCY; ARTICLE; ATHEROSCLEROSIS; BONE EROSION; BONE NECROSIS; CATARACT; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIABETES MELLITUS; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DISEASE ACTIVITY; DIVERTICULITIS; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; GLAUCOMA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFECTION; INTRAOCULAR HYPERTENSION; JOINT DESTRUCTION; JOINT RADIOGRAPHY; NEUROENDOCRINE DISEASE; PEPTIC ULCER; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SCORING SYSTEM; VISUAL DISORDER; ASTHMA; BONE DENSITY; BONE RADIOGRAPHY; BONE REMODELING; CYTOKINE RELEASE; DRUG SAFETY; INFLAMMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOLYSIS; PROVOCATION TEST; SIDE EFFECT; STOMACH HEMORRHAGE; STOMACH PERFORATION; STOMACH ULCER; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; GLUCOCORTICOIDS; HUMANS; RISK ASSESSMENT;

EID: 4944228042     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Empire Rheumatism Council Sub-Committee: Multi-center controlled trial comparing cortisone acetate and acetyl salicylic acid in the long-term treatment of rheumatoid arthritis. Results of up to one year. Ann Rheum Dis 1955; 14: 353-63.
2. Empire Rheumatism Council Sub-Committee: Multi-center controlled trial comparing cortisone acetate and acetyl salicylic acid in the long-term treatment of rheumatoid arthritis. Results of three years of treatment. Ann Rheum Dis 1957; 16: 277-89.
3. VAN EVERDINGEN AA, JACOBS JWG, VAN REESEMA DR, BIJLSMA JWJ: Low dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease modifying properties and side effects. A double-blind placebo-controlled clinical trial. Ann Intern Med 2002; 136: 1-12.
4. BOERS M, VERHOVEN AC, MARKUSSE HM et al.: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-18.
5. KIRWAN JR, and the Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group: The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995; 333: 142-6.
6. EGGERT M, SCHULZ M, NEECK G: Molecular mechanisms of glucocorticoid action in rheumatic autoimmune diseases. J Steroid Biochem Mol Biol 2001; 77: 185-91.
7. BARNES PJ, ADCOCK I: Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 1993; 14: 436-41.
8. PINCUS T, MARCUM SB, CALLAHAN LF: Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992; 19: 1885-94.
9. SOLOMON DH, KATZ JN, JACOBS JP, LA TOURETTE AM, COBLYN J: Management of glucocorticoid-induced osteoporosis in patients with rheumatoid athritis: Rates and predictors of care in an academic rheumatology practice. Arthritis Rheum 2002; 46: 3136-42.
10. HICKLING P, JACOBY RK, KIRWAN JR, and the Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group: Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Br J Rheumatol 1998; 37: 930-6.
11. LANDEWE RBM, BOERS M, VERHOEVEN AC et al.: COBRA combination therapy in patients with early rheumatoid arthritis. Arthritis Rheum 2002; 46: 347-56.
12. BIJLSMA JWJ, BOERS M, SAAG KG, FURST DE: Glucocorticoids in the treatment of early and late rheumatoid arthritis. Ann Rheum Dis 2003; 62: 1033-7.
13. KIRWAN JR: Systemic corticosteroids in rheumatology. In HOCHBERG MC, SILMAN AJ, SMOLEN JS, WEINBLATT ME, WEISMAN MH (Eds.): Rheumatology, 3rd ed., Vol. 1. Philadelphia, Mosby 2003: 385-92.
14. WERB Z: Biochemical actions of glucocorticoids on macrophages in culture-specific inhibition of elastase, collagenase and plasminogen activator functions. J Exp Med 1978; 147: 1695-712.
15. BOUMPAS DT, CHROUSOS GP, WILDER RL et al.: Glucocorticoid therapy for immune-mediated diseases: Basic and clinical correlates. Ann Intern Med 1993; 119: 1198-208.
16. STEIN CM, PINCUS T: Glucocorticoids. In RUDDY S and HARRIS ED JR (Eds.): Textbook of Rheumatology, 5th ed., Philadelphia, W.B. Saunders 2001: 823-40.
17. SAAG KG, KIRWAN JR: Glucocorticoid therapy in rheumatoid arthritis. In TSOKOS GC (Ed.): Modern Therapeutics in Rheumatic Diseases. Totowa, Humana Press 2001.
18. REID IR: Glucocorticoid-induced osteoporosis. J Clin Densitometry 1998; 1: 65-73.
19. STEINBUCH M, YOUKET TE, COHEN S: Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporosis Int 2004; 15: 323-8.
20. BALTZAN MA, SUISSA S, BAUER DC, CUMMINGS SR: Hip fractures attributable to corticosteroid use (research letters). Lancet 1999; 353: 1327.
21. COOPER C, COUPLAND C, MITCHELL M: Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995; 54: 49-52.
22. PEAT ID, HEALY S, REID DM, RALSTON SH: Steroid induced osteoporosis: an opportunity for prevention ? Ann Rheum Dis 1995; 54: 66-8.
23. WALSH LJ, WONG CA, PRINGLE M, TATTERSFIELD AE: Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996; 313: 344-6.
24. BUCKLEY LM: Clinical and diagnostic features of glucocorticoid-induced osteoporosis. Clin Exp Rheumatol 2000;18 (Suppl. 21): S41-43.
25. VERHOEVEN AC, BOERS M: Limited bone loss due to corticosteroids: a systematic review of prospective studies in rheumatoid arthritis and other diseaes. J Rheumatol 1997; 24: 1495-503.
26. NISHIMURA J, IKUYAMA S: Glucocorticoid-induced osteoporosis: pathogenesis and management. J Bone Miner Metab 2000; 18:350-2.
27. de NIJS RNJ, JACOBS JWG, GIJLSMA JWJ et al. on behalf of the Osteoporosis Working Group of the Dutch Society for Rheumatology: Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. Rheumatology 2001; 40: 1375-83.
28. VAN STAA T, LEUFKENS H, ABENHAIM L, ZHANG B, COOPER C: Use of oral coticosteroids and risk of fractures. J Bone Miner Res 2000; 15: 993-1000.
29. CANALIS E, DELANY AM: Mechanisms of glucocorticoid action in bone. Ann New York Acad Sci 2002; 966: 73-81.
30. REID IR, IBBETSON HK: Evidence for decreased tubular reabsorption of calcium in glucocorticoid-treated asthmatics. Horm Res 1987;27: 200-4.
31. RUBIN MR, BILEZIKIAN JP: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: A re-examination of the evidence. J Clin Endocrinol Metab 2002; 87: 4033-41.
32. CARBONARE L, ARLOT ME, CHAVASSIEUX PM, ROUX JP, PORTERO NR, MEUNIER PJ: Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Min Res 2001; 16: 97-103.
33. PATSCHAN D, LODDENKEMPER K, BUTTGEREIT F: Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone 2001; 29: 498-505.
34. ZIZIC TM, MARCOUX C, HUNGERFORD DS: Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. Am J Med 1985; 79: 596-604.
35. VREDEN SGS, HERMUS ARMM, VAN LIESSUM PA et al.: Aseptic bone necrosis in patients on glucocorticoid replacement therapy. Neth J Med 1991; 39: 153-7.
36. SAAG K KR, CALDWELL J, BRASINGTON R et al.: Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse events. Am J Med 1994; 96: 115-23.
37. CALDWELL JR, FURST DE: The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis. Semin Arthritis Rheum 1991; 21: 1-11.
38. SKALKA HW, PRCHAL JT: Effect of corticosteroids on cataract formation. Arch Ophthalmol 1980; 98: 1773-7.
39. KLEIN BE, KLEIN R, LEE KE, DANFORTH LG: Drug use and five-year incidence of age-related cataracts: The Beaver Dam Eye Study. Opthalmology 2001; 108: 1670-4.
40. CUMMING RG, MITCHELL P, LEEDER SR: Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337: 8-14.
41. WOLFE F, FURST D, LANE N et al.: Substantial increases in important adverse events follow low dose prednisone therapy of rheumatoid arthritis (RA). Arthritis Rheum 1995; 38: S312.
42. GARBE E, LeLORIER J, BIOBIN J-F, SUISSA S: Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet 1997; 350: 979-82.
43. MESSER J, REITMAN D, SACKS HS, SMITH HJ, CHALMERS TC: Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983; 309: 21-4.
44. PIPER JM, RAY WA, DAUGHERTY JR, GRIFFIN MR: Corticosteroid use and peptic ulcer disease: role of noncorticosteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114: 735-40.
45. GABRIEL SE, JAAKKIMAINEN L, BOMBARDIER C: Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 115: 787-96.
46. BOMBARDIER C, LAINE L, REICIN A et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8.
47. GARCIA RODRIGUEZ LA, HERNANDEZ-DIAZ S: The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res 2001; 3: 98-101.
48. MPOFU S, MPOFU CM, HUTCHINSON D, MAIER AE, DODD SR, MOOTS RJ: Steroids, non-steroidal anti-inflammatory drugs, and sigmoid diverticular abscess performation in rheumatic conditions. Ann Rheum Dis 2004; 63: 588-90.
49. PETRI M, PEREZ-GuTTHANN S, SPENCE D et al.: Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93: 513-9.
50. EL-SHABOURY AH, HAYES TM: Hyperlipidemia in asthmatic patients receiving long-term steroid therapy. Br Med J 1973; 2: 85-6.
51. BECKER DM, CHAMBERLAIN B, SWANK R et al.: Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med 1988; 85: 632-8.
52. CATTRAN DC, STEINER G, WILSON DR, FENTON SSA: Hyperlipidemia after renal transplantation: natural history and pathophysiology. Ann Intern Med 1979; 91: 554-9.
53. PETRI M, SPENCE D, BONE LR et al.: Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: Prevalence, recognition by patients, and preventative practices. Medicine 1992; 71: 291-302.
54. ISOMAKI HA, MEUTRU O, KOOTA K: Death rate and causes of death in patients with rheumatoid arthritis. Scand J Rheumatol 1975; 4: 205-8.
55. MUTRU O, LAAKSO M, ISOMAKI H, KOOTA K: Ten year mortality and causes of death in patients with rheumatoid arthritis. Br Med J 1985; 290: 1797-9.
56. WOLFE F, MITCHELL DM, SIBLEY JT et al.: The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481-94.
57. WALLBERG-JONSSON S, OHMAN ML, DAHLQUIST SR: Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997; 24: 445-51.
58. BOERS M, NURMOHAMED MT, DOELMAN CJA et al.: Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 842-5.
59. PARK Y-B, AHN C-W, CHOI HK, LEE S-H, IN B-H, LEE H-C, NAM C-M, LEE S-K: Atherosclerosis in rheumatoid arthritis: Morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 2002; 46: 1714-9.
60. ALKAABI JK, HO M, LEVISON R, PULLAR T, BELCH JJF: Rheumatoid arthritis and macrovascular disease. Rheumatology 2003; 42: 292-7.
61. JACKSON SHD, BEEVERS DG, MYERS K: Does long-term low-dose corticosteroid therapy cause hypertension? Clin Sci 1981; 61: 381s-383s.
62. WHITWORTH JA: Mechanisms of glucocorticoid-induced hypertension. Kidney Int 1987; 31: 1213-24.
63. GURWITZ JH, BOHN RL, GLYNN RJ, MONANE M, MOGUN H, AVORN J: Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994; 154: 97-101.
64. MILLER SE, NEILSON JM: Clinical features of the diabetic syndrome appearing after steroid therapy. Postgrad Med J 1964; 40: 660.
65. BYNY RL: Withdrawal from glucocorticoid therapy. N Engl J Med 1974; 294: 30-2.
66. SERGENT J, LOCKSHIN M, KLEMPER M, LIPSKY B: Central nervous system disease in systemic lupus erythematosis: therapy and prognosis. Am J Med 1975; 58: 644.
67. FAUCI AS: Glucocorticosteroid therapy: Mechanisms of action and clinical considerations. Ann Intern Med 1976; 84: 304-15.
68. YALE SH, LIMPER AH: Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illnesses and prior corticosteroid therapy. Mayo Clin Proc 1996; 71: 5-13.
69. STUCK A, MINDER C, FREY F: Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989; 11: 954-63.